1. Home
  2. APLM vs LNKS Comparison

APLM vs LNKS Comparison

Compare APLM & LNKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • LNKS
  • Stock Information
  • Founded
  • APLM 2016
  • LNKS 1995
  • Country
  • APLM United States
  • LNKS Malaysia
  • Employees
  • APLM N/A
  • LNKS N/A
  • Industry
  • APLM Blank Checks
  • LNKS
  • Sector
  • APLM Finance
  • LNKS
  • Exchange
  • APLM Nasdaq
  • LNKS NYSE
  • Market Cap
  • APLM 7.7M
  • LNKS 9.1M
  • IPO Year
  • APLM N/A
  • LNKS 2024
  • Fundamental
  • Price
  • APLM $6.16
  • LNKS $0.50
  • Analyst Decision
  • APLM Strong Buy
  • LNKS
  • Analyst Count
  • APLM 2
  • LNKS 0
  • Target Price
  • APLM $425.00
  • LNKS N/A
  • AVG Volume (30 Days)
  • APLM 42.6K
  • LNKS 273.8K
  • Earning Date
  • APLM 04-15-2025
  • LNKS 05-11-2025
  • Dividend Yield
  • APLM N/A
  • LNKS N/A
  • EPS Growth
  • APLM N/A
  • LNKS N/A
  • EPS
  • APLM N/A
  • LNKS N/A
  • Revenue
  • APLM $2,101,000.00
  • LNKS $4,754,489.00
  • Revenue This Year
  • APLM N/A
  • LNKS N/A
  • Revenue Next Year
  • APLM N/A
  • LNKS N/A
  • P/E Ratio
  • APLM N/A
  • LNKS N/A
  • Revenue Growth
  • APLM 70.54
  • LNKS N/A
  • 52 Week Low
  • APLM $6.20
  • LNKS N/A
  • 52 Week High
  • APLM $63.00
  • LNKS N/A
  • Technical
  • Relative Strength Index (RSI)
  • APLM 42.37
  • LNKS N/A
  • Support Level
  • APLM $6.50
  • LNKS N/A
  • Resistance Level
  • APLM $8.00
  • LNKS N/A
  • Average True Range (ATR)
  • APLM 1.36
  • LNKS 0.00
  • MACD
  • APLM -0.22
  • LNKS 0.00
  • Stochastic Oscillator
  • APLM 5.93
  • LNKS 0.00

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About LNKS LINKERS INDUSTRIES LIMITED

Linkers Industries Ltd is a company which acts as a manufacturer and a supplier of wire, cable harnesses with their manufacturing operations in Malaysia. Wire/cable harness refers to an assembly of wires/cables bound together with straps, cable ties and electrical tapes to transmit signals or electrical power. Company works closely with customers in each stage of a product's life cycle, including design, prototyping and production. Geographically company provides services in Thailand, Malaysia, Switzerland, United States of America, and many others, maximum revenue gained from Thailand.

Share on Social Networks: